Development Pipeline
PF-655
QPI-1002
QPI-1007
Program for Pipeline siRNAs
Disease Indications
Letter from the CEO
Company Profile
Management
Board of Directors
Mission, Vision and Values
Licensing Partners
News
Careers
Website Disclaimer
Overview
News
Overview
Current Collaborations
ClinicalStudies
SiRNA
Intellectual Property
About Us
Product Candidates
Research & Development
Investor Relations
Contact
Development Pipeline
PF-655
QPI-1002
QPI-1007
Program for Pipeline siRNAs
Disease Indications
Letter from the CEO
Company Profile
Management
Board of Directors
Mission, Vision and Values
Licensing Partners
News
Careers
Website Disclaimer
Overview
News
Overview
Current Collaborations
ClinicalStudies
SiRNA
Intellectual Property
About Us
Product Candidates
Research & Development
Investor Relations
Contact
Development Pipeline
PF-655 (RTP801i14)
Partner:
Pfizer
Disease:
Diabetic Macular Edema
Disease:
Wet Age-related Macular Degeneration
QPI 1002(I5NP)
Partner:
Option granted to Novartis
Disease:
Acute Kidney Injury (AKI)
Disease:
Kidney Transplantation (DGF)
QPI 1007
Disease:
Non-arteritic Anterior Ischemic Optic Neuropathy
Disease:
Glaucoma
Programs for Pipeline siRNAs in several diseases
Development Pipeline
PF-655
QPI-1002
QPI-1007
Program for Pipeline siRNAs
Disease Indications
Home
Products
Contact
©2007 Quark Pharmaceuticals, Inc.